SecBot SecBot
Insider Buy ·Filed Nov 6, 2026

AGMB

AgomAb Therapeutics NV
NEUTRAL
Impact 2/10
Horizonimmediate Processed10d 20h ago SEC0001445826-26-000018
Insider cluster: 1 insiders, $104K total
Actionable Insight • Neutral

The purchase is too small relative to market cap to signal material conviction. Monitor for additional insider buying or a C-suite purchase to confirm a bullish signal.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$7.64
T+0 close · Nov 6, 2026 · via day close
Latest settled
−16.70%
T+5 · $6.36
Vs SPY
−19.29%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $7.64entry
  2. T+1 · 8d ago −1.11%α −3.48% · $7.55
  3. T+5 · 4d ago −16.70%α −19.29% · $6.36
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director David R. Epstein purchased 15,000 shares of AgomAb Therapeutics for $104K in three open-market trades on November 5, 2026, with no 10b5-1 plan. The total value represents 0.03% of the company's $337M market cap, a trivial amount relative to company size.

Key Financial Metrics

Direction
buying
Total Value
$104.0K
Insiders
1

Key Facts

  • Director David R. Epstein bought 15,000 shares total in three open-market trades on November 5, 2026
  • Total purchase value: $104K (0.03% of $337M market cap)
  • All trades were open-market purchases (Form 4 code P) with no 10b5-1 plan
  • Buyer is a Director, not C-suite (CEO/CFO)

Financial Impact

$104K total insider purchase, 0.03% of market cap

Risk Factors

  • Purchase value is trivial relative to market cap (0.03%), limiting signaling value
  • Buyer is a Director, not a C-suite executive, reducing informational weight

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001445826-26-000018

Track record

16 reports on AGMB

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +6.98% at T+5 after the Apr 24, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Neutral 3/10 Entry $6.36 Now $5.97 −6.13% settles Nov 23
  2. Nov 6, 202610d ago Insider Buy Neutral 2/10 Viewing Entry $7.64 to $6.36 Now $5.97 −21.81% ▼ −16.70% −19.29% vs SPY
  3. Oct 22, 202625d ago Insider Buy Bullish 4/10 Entry $9.26 to $7.95 Now $5.97 −35.53% ▼ −14.15% −14.85% vs SPY
  4. Oct 13, 20264w ago 6-K Bullish 5/10 Entry $8.69 to $9.11 Now $5.97 −31.30% ▲ +4.83% +4.38% vs SPY
  5. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $8.69 to $9.11 Now $5.97 −31.30% ▲ +4.83% +4.38% vs SPY
  6. Oct 1, 20266w ago 6-K Bullish 7/10 Entry $8.65 to $9.22 Now $5.97 −30.98% ▲ +6.59% +5.29% vs SPY
  7. Oct 1, 20266w ago Press Release Bullish 7/10 Entry $8.65 to $9.22 Now $5.97 −30.98% ▲ +6.59% +5.29% vs SPY
  8. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $12.16 to $11.49 Now $5.97 −50.90% ▼ −5.51% −7.64% vs SPY
  9. Sep 14, 20269w ago Press Release Bullish 6/10 Entry $12.16 to $11.49 Now $5.97 −50.90% ▼ −5.51% −7.64% vs SPY
  10. Sep 11, 20269w ago 6-K Neutral 2/10 Entry $12.28 to $11.70 Now $5.97 −51.38% ▼ −4.72% −4.83% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 5h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026